Key Highlights

  • 122,417,458 shares were recorded as eligible for voting on the July 8 special meeting.
  • 98,726,611 shares participated, equating to roughly 80.6% of the voting-eligible shares.
  • Shareholders approved the merger, meeting the required majority-share condition for closing.

Catalyst Pharmaceuticals (NASDAQ: CPRX) announced that its shareholders have formally approved a merger agreement with Angelini Pharma. The decision was made during a special meeting held on July 8, 2026, and will lead to the resignation of the company’s current board of directors once the transaction is finalized.

Merger Agreement Details

The merger agreement, signed on May 6, 2026, outlines a transaction in which Angelini Cielo Inc. An entity linked to Angelini Pharma, will merge with Catalyst. Following the deal, Catalyst will continue operations under the ownership of its new parent company, integrating into the broader structure of the acquiring firm. This move aligns with industry trends where pharmaceutical companies seek strategic combinations to strengthen market position and expand therapeutic portfolios.

Shareholder Vote Outcome

The record date for the special meeting was set on June 3, 2026, with 122,417,458 shares determined to be eligible to vote. During the meeting, 98,726,611 shares were cast either in person or by proxy, representing approximately 80.6% of the eligible shares. This level of participation satisfied the required threshold for the merger to move forward.

Tierney, M.D. Have committed to resigning once the merger is completed. The decision to step down is described as part of the transition process rather than a response to any disagreements over corporate strategy or operations.

Compensation Advisory Vote

A separate proposal seeking shareholder input on executive compensation tied to the merger did not receive the necessary support. While the vote was advisory and non-binding, its failure does not impact the merger’s progress toward completion.

Adjournment Provision

No motion to adjourn the meeting was required, as the merger proposal received sufficient approval during the July 8 session.

Forward-Looking Statements

Catalyst Pharmaceuticals has noted that its future projections involve certain risks and uncertainties. These include potential challenges related to regulatory approvals, integration of operations, and possible effects on workforce dynamics and product reimbursement. The company has directed stakeholders to its proxy filing for a detailed discussion of these risks.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.